- Home
- LOAN vs IMA Comparison
LOAN vs IMA Comparison
Compare LOAN & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOAN | IMA |
|---|---|---|
| Founded | 1989 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 54.8M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | LOAN | IMA |
|---|---|---|
| Price | $4.56 | $5.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 31.3K | ★ 391.7K |
| Earning Date | 04-16-2026 | 05-15-2026 |
| Dividend Yield | ★ 9.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $8,666,307.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.18 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.13 | $3.94 |
| 52 Week High | $5.85 | $17.50 |
Technical Indicators
Market Signals| Indicator | LOAN | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 58.05 |
| Support Level | $4.33 | $5.52 |
| Resistance Level | $4.90 | $7.04 |
| Average True Range (ATR) | 0.17 | 0.45 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 43.75 | 71.74 |
Price Performance
Historical ComparisonAbout LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.